Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07303439

Randomised Trial of Dual Device Treatment Involving Drug-coated Balloon Angioplasty and Drug-eluting Stent Implantation Compared to Single Device Treatments in Patients With Diabetes Mellitus

Led by Royal College of Surgeons, Ireland · Updated on 2025-12-24

120

Participants Needed

1

Research Sites

312 weeks

Total Duration

On this page

Sponsors

R

Royal College of Surgeons, Ireland

Lead Sponsor

C

Cardiovascular Research Institute Dublin

Collaborating Sponsor

AI-Summary

What this Trial Is About

Purpose of this study: The purpose of the study is to find out whether using a drug coated balloon in combination with a drug-eluting stent is better than the standard practice of using either device on its own. This study is specifically looking at patients with diabetes who have coronary artery disease. This means that their arteries become restricted or blocked, and these restrictions or blockages are called lesions. The study will look at diabetic patients undergoing treatment for lesions in segments of their coronary arteries that have not previously been treated with stents. These are called 'de novo' lesions. The treatment being investigated: In this study, we are comparing two devices, either used together or on their own to treat coronary artery disease. These devices are commercially available in Europe and carry the mark. This study is being carried out to compare the effectiveness of combining the two devices or using them individually: * Pantera® Lux® Paclitaxel Drug Coated Balloon, abbreviated Pantera® Lux® (DCB) A drug coated balloon is a balloon which is covered by an anti-proliferative drug. * Orsiro® biodegradable polymer Sirolimus Eluting Stent Orsiro® (DES) A stent is a short, wire mesh tube that acts like a scaffold to keep your artery open. A drug eluting stent is coated with medication that reduces the risk of the artery becoming blocked again. Both drug-eluting stents and drug-coated balloons are used routinely for the treatment of 'de novo' coronary artery disease in Europe. How will the study be carried out? This study is being conducted in 4 hospitals across Ireland. We aim to recruit 120 participants s in this study. If you agree to participate in this study and sign the informed consent form, you will be asked to participate in the screening process, which will determine if you meet the conditions to participate in the study. You will be "randomised" into one of the 3 study groups. Randomisation means that you are put into a group by chance (similarly to the roll of a dice). Neither you nor your doctor can choose the group you will be in. You will not know which group you were placed in until the end of the study. However, your doctor will know which study group you were placed in. * 40 patients will be treated with Pantera® Lux® (Drug Coated Balloon) only * 40 patients will be treated with Orsiro® (Drug Eluting Stent) only * 40 patients will be treated with a combination of both Pantera® Lux® (Drug Coated Balloon) and Orsiro® (Drug Eluting Stent). If you agree to participate in the study you will be invited to come back for a check-up angiogram 6 months after your procedure to make sure that the treatment has been a success. This is sometimes done in normal clinical practice, but it is not done routinely. You will not be charged for this additional test.

CONDITIONS

Official Title

Randomised Trial of Dual Device Treatment Involving Drug-coated Balloon Angioplasty and Drug-eluting Stent Implantation Compared to Single Device Treatments in Patients With Diabetes Mellitus

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with acute or chronic coronary syndrome
  • Diagnosis of diabetes
  • Patients undergoing PCI for de novo lesions in native coronary arteries
  • Patients able and willing to provide written informed consent
  • Age 65 18 years.
  • Patients able and willing to comply with the study procedures and follow-up.
  • All angiographic inclusion criteria fulfilled: the lesion is treatable, the guidewire has crossed the lesion, the lesion has been successfully pre-dilated with balloon expansion complete, residual stenosis less than 50%, TIMI flow greater than 2, and no flow-limiting dissection seen.
Not Eligible

You will not qualify if you...

  • Lesions located at the left main coronary artery
  • Patient presents with a ST-elevation myocardial infarction (STEMI)
  • Patient with acute cardiac decompensation or acute cardiogenic shock
  • Patient with impaired renal function (glomerular filtration rate < 30 mL/min/1.73 m2)
  • Severe in-stent calcification preventing sufficient expansion of the drug coated balloon unless adequately pre-treated
  • Evidence of high-grade dissection (NHLBI class C or greater) at baseline
  • Known hypersensitivity or contraindication to sirolimus, paclitaxel, heparin, aspirin, thienopyridines, or iodinated contrast that cannot be pre-treated
  • Patients unable to take dual antiplatelet therapy for 6-12 months
  • Pregnant or breastfeeding females or females intending to become pregnant during the study
  • Currently enrolled in other investigational device or drug trial with primary endpoint not yet reached
  • Anticipated difficulties completing angiographic surveillance
  • Life expectancy less than 12 months
  • Lacking mental capacity to provide informed consent
  • Inadequate understanding of English to comprehend study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mater Private Hospital

Dublin, County Dublin, Ireland, D07 KWR1

Actively Recruiting

Loading map...

Research Team

A

Amy Carswell, MSc.

CONTACT

C

Carmen Farrelly, BSc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here